Global pharmaceutical company Strides Shasun Limited has announced that it has received approval from the United States Food and Drug Administration (USFDA) for Abacavir tablets USP (300 mg), which is used for the treatment of HIV-1 infection in combination with other antiretroviral agents.
The product, to be launched immediately, will be manufactured at the companys USFDA-approved facility at Bangalore and marketed by Strides in the US Market.
According to IMS data, the US market for Abacavir is approximately $30 million.
Strides Shasun has four business verticals — regulated markets, emerging markets, institutional business and active pharmaceutical ingredients. The company has global manufacturing foot print with 13 manufacturing facilities spread across three continents including five USFDA-approved facilities and eight facilities for the emerging markets.